



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: October 9, 2009

To: NCCTG Primary Clinical Research Associates

From: Alicia Elsing
Research Protocol Specialist

Re: N0321, Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

The Eligibility Checklist has been revised as follows:

| Form Title | Brief Description of Edit |
|-----------------------------|---|
| N0321 Eligibility Checklist | <ul style="list-style-type: none">• The registration process was updated to reflect Remote Registration availability.• Corrections to the optional translational research component from Phase I - phone call to Registration Office for registration; to Phase II - incorporated remote data capture (RDC) verbiage from section 6.22.• Grouping Factor verbiage for Phase I was marked as "NA" with a note that states "<i>(As of Addendum 12, the Phase I portion of the study is complete)</i>"• All dose levels deleted under Descriptive Factors with the exception of "6" which is the defined Addendum 12 dose level.• Collection of dose and levels is no longer required; deleted dose and level lines along with corresponding asterisks under the "Assigned Treatment" section. |

If you have any questions, please feel free to contact me at 507/284-4852.

AE/dg
Enclosure